Mario Gabelli's ABT Position Overview
Mario Gabelli (via Gamco Investors, Inc. Et Al) currently holds 22,358 shares of Abbott Laboratories (ABT) worth $2.99 M, representing 0.03% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Mario Gabelli has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2013, adding 103,382 shares. Largest reduction occurred in Q3 2014, reducing 61,770 shares.
Analysis based on 13F filings available since 2013 Q2
Mario Gabelli's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Mario Gabelli
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +85,597 | Add 0.00% | 85,596 | $34.88 |
| Q3 2013 | +8,205 | Add 9.59% | 93,801 | $33.19 |
| Q4 2013 | +103,382 | Add 110.21% | 197,183 | $38.33 |
| Q1 2014 | -28,696 | Reduce 14.55% | 168,487 | $38.51 |
| Q2 2014 | -7,780 | Reduce 4.62% | 160,707 | $40.90 |
| Q3 2014 | -61,770 | Reduce 38.44% | 98,937 | $41.59 |
| Q4 2014 | -33,600 | Reduce 33.96% | 65,337 | $45.01 |
| Q1 2015 | -50 | Reduce 0.08% | 65,287 | $46.33 |
| Q2 2015 | -4,255 | Reduce 6.52% | 61,032 | $49.07 |
| Q3 2015 | -43,407 | Reduce 71.12% | 17,625 | $40.23 |
| Q1 2016 | -3,930 | Reduce 22.30% | 13,695 | $41.84 |
| Q2 2016 | -10 | Reduce 0.07% | 13,685 | $39.31 |
| Q3 2016 | +10 | Add 0.07% | 13,695 | $42.28 |
| Q4 2016 | -70 | Reduce 0.51% | 13,625 | $38.39 |
| Q1 2017 | +30,008 | Add 220.24% | 43,633 | $44.42 |
| Q2 2017 | +24,000 | Add 55.00% | 67,633 | $48.62 |
| Q3 2017 | -905 | Reduce 1.34% | 66,728 | $53.37 |
| Q4 2017 | -445 | Reduce 0.67% | 66,283 | $57.07 |
| Q1 2018 | -2,168 | Reduce 3.27% | 64,115 | $59.92 |
| Q2 2018 | -3,410 | Reduce 5.32% | 60,705 | $60.98 |
| Q3 2018 | -215 | Reduce 0.35% | 60,490 | $73.37 |
| Q4 2018 | +7,118 | Add 11.77% | 67,608 | $72.33 |
| Q1 2019 | -5,481 | Reduce 8.11% | 62,127 | $79.93 |
| Q2 2019 | -18,118 | Reduce 29.16% | 44,009 | $84.10 |
| Q3 2019 | +14,384 | Add 32.68% | 58,393 | $83.67 |
| Q4 2019 | +80 | Add 0.14% | 58,473 | $86.86 |
| Q1 2020 | -15,315 | Reduce 26.19% | 43,158 | $78.92 |
| Q2 2020 | -18,033 | Reduce 41.78% | 25,125 | $91.42 |
| Q3 2020 | +390 | Add 1.55% | 25,515 | $108.84 |
| Q4 2020 | -300 | Reduce 1.18% | 25,215 | $109.50 |
| Q1 2021 | -1,164 | Reduce 4.62% | 24,051 | $119.83 |
| Q2 2021 | -146 | Reduce 0.61% | 23,905 | $115.92 |
| Q3 2021 | +25 | Add 0.10% | 23,930 | $118.14 |
| Q4 2021 | +1,542 | Add 6.44% | 25,472 | $140.74 |
| Q1 2022 | -1,672 | Reduce 6.56% | 23,800 | $118.36 |
| Q2 2022 | -177 | Reduce 0.74% | 23,623 | $108.67 |
| Q3 2022 | +220 | Add 0.93% | 23,843 | $96.76 |
| Q4 2022 | +3,325 | Add 13.95% | 27,168 | $109.79 |
| Q1 2023 | -73 | Reduce 0.27% | 27,095 | $101.26 |
| Q2 2023 | -3,384 | Reduce 12.49% | 23,711 | $109.02 |
| Q3 2023 | -67 | Reduce 0.28% | 23,644 | $96.85 |
| Q4 2023 | +295 | Add 1.25% | 23,939 | $110.07 |
| Q1 2024 | -916 | Reduce 3.83% | 23,023 | $113.66 |
| Q2 2024 | -66 | Reduce 0.29% | 22,957 | $103.91 |
| Q3 2024 | -387 | Reduce 1.69% | 22,570 | $114.01 |
| Q4 2024 | -340 | Reduce 1.51% | 22,230 | $113.11 |
| Q1 2025 | -95 | Reduce 0.43% | 22,135 | $132.65 |
| Q2 2025 | +1,223 | Add 5.53% | 23,358 | $136.01 |
| Q3 2025 | -1,000 | Reduce 4.28% | 22,358 | $133.94 |
Mario Gabelli's Abbott Laboratories Investment FAQs
Mario Gabelli first purchased Abbott Laboratories (ABT) in Q2 2013, acquiring 85,596 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mario Gabelli has held Abbott Laboratories (ABT) for 50 quarters since Q2 2013.
Mario Gabelli's largest addition to Abbott Laboratories (ABT) was in Q4 2013, adding 197,183 shares worth $7.56 M.
According to the latest 13F filing for Q3 2025, Mario Gabelli's firm, Gamco Investors, Inc. Et Al, owns 22,358 shares of Abbott Laboratories (ABT), valued at approximately $2.99 M.
As of the Q3 2025 filing, Abbott Laboratories (ABT) represents approximately 0.03% of Mario Gabelli's publicly disclosed stock portfolio, making it one of their key holdings.
Mario Gabelli's peak holding in Abbott Laboratories (ABT) was 197,183 shares, as reported at the end of Q4 2013.